Core Viewpoint - InMode's management believes that the multi-year downturn in demand is stabilizing, with expectations for flat revenue in 2026 after two years of decline, while focusing on building infrastructure to support recovery, particularly in North America [4][6]. Organizational Changes - The company has restructured its North American organization by appointing a new president and adding two vice presidents, creating a "presidential suite" to enhance execution [1]. - A bifurcation of the salesforce has occurred to focus on wellness segments, including dedicated teams for eye care and women's and men's health [6][5]. Market Demand and Strategy - InMode anticipates that demand for aesthetic procedures will eventually return, although current softness is widespread and not limited to energy-based devices [2]. - The company is expanding its offerings beyond aesthetics into women's health and eye care, with plans to pursue ENT as a potential new area [7][8]. Product Development - InMode is broadening its product line to include lasers, aiming to become a "one-stop shop" for energy-based devices, despite facing gross margin pressure due to the commodity nature of lasers [9][10][11]. - The company has launched a Pico laser and plans to introduce an Erbium laser later this year, with a new version of Morpheus8 expected toward year-end [16][17]. Financial Outlook - The CFO indicated that patient demand is a significant headwind, with higher interest rates impacting capital equipment sales, but the focus remains on stabilizing revenue and improving margins [2][4][14]. - InMode is evaluating various capital allocation strategies, including share buybacks, dividends, and potential M&A to support expansion into new areas [12]. Market Dynamics - The company recognizes that margin performance is heavily influenced by product mix, particularly in North America, which is its most profitable region [14]. - InMode is monitoring external factors such as tariffs, which could impact margins positively if resolved [14].

Summary of InMode Conference Call Company Overview - **Company**: InMode - **Industry**: Medical Devices, specifically in aesthetic treatments Key Points Current Operational Challenges - InMode is currently operating at approximately **60% manufacturing capacity** due to regional instability and threats from neighboring countries [5][6] - The company faces significant **logistical challenges** with shipping, as major carriers like DHL and FedEx are not operating flights to Israel, leading to increased shipping costs [6][7] - Employee attendance is affected by school closures, impacting workforce availability [6] Inventory Management - InMode has built a **safety inventory** of finished goods and components over the past two years, which is currently being utilized to meet market demands despite shipping challenges [11] - The company has shipped products to subsidiaries globally to fill gaps caused by local disruptions [11] Share Buyback Program - InMode has executed a **share buyback program**, purchasing shares worth **$508 million** to date, with an additional **$85 million to $90 million** approved for buyback, totaling around **$600 million** over the last 3.5 years [14][15] - The company aims to maintain liquidity for potential M&A opportunities, targeting acquisitions in the range of **$500 million to $1 billion** [17] Market Trends and Customer Insights - There is a **stabilization** in patient activity and treatment usage, with no significant growth or decline observed [19] - High interest rates on leasing (14%-15%) are affecting customer purchasing decisions, particularly in the U.S. market [20] - The company anticipates potential growth in 2027, contingent on stabilization in 2026 and new product launches [22][33] Product and Technology Development - InMode is focusing on expanding its portfolio to include **non-invasive technologies**, which now contribute nearly **20%** to its revenue [34] - The company is developing new laser technologies to complement its existing RF energy products, aiming for a competitive edge in the market [36][39] - A dedicated team for the **dry eye treatment** platform has been established, with plans to submit for FDA approval for a new RF-based study [41][42] Geographic and Structural Changes - InMode has restructured its North American operations to unify management, aiming for improved efficiency and sales performance [29][30] - The company is also exploring growth opportunities in Asia, particularly in China and Korea, where it currently has limited market presence [46][47] Financial Outlook - Gross margins are impacted by a shift towards more laser-based devices, which traditionally have lower margins, and by tariffs affecting U.S. operations [49][50] - Despite current challenges, there is optimism about the recovery of demand for aesthetic procedures, which is expected to improve margins in the future [51] Additional Insights - The company is cautious about future guidance due to macroeconomic uncertainties and ongoing regional instability [22][50] - InMode's management is actively monitoring the effectiveness of recent organizational changes and is prepared to make further adjustments as necessary [30][32]

InMode (NasdaqGS:INMD) FY Conference Summary Company Overview - **Company**: InMode - **Industry**: Aesthetic medical devices - **Conference Date**: March 11, 2026 Key Points Market Outlook - After two years of declining business, InMode expects 2026 to be flat on the top line, with hopes for improvement thereafter [5][7] - There are signs of recovery in end markets, although caution is advised regarding optimism [2][5] - Demand for aesthetic procedures is anticipated to return, despite recent declines across various segments, including energy-based devices and injectables [7][10] Organizational Changes - InMode has restructured its U.S. team, appointing a new president and two new VPs to enhance leadership and execution [10][12] - A dedicated sales team has been established to focus on non-aesthetic wellness devices, including eye care and women's health products [12][13] Strategic Focus - The company is expanding into non-aesthetic markets, including women's health and ophthalmology, with plans to enter ENT next year [22][23] - InMode is working on obtaining U.S. indications for dry eye treatment, which is expected to boost sales once achieved [22][24] Product Development - InMode has introduced new laser products, including a CO2 laser and a Pico laser, to complement its existing offerings [27][28] - The strategy aims to create a one-stop shop for customers, reducing reliance on competitors for energy-based devices [27][28] Financial Considerations - Margins are under pressure due to the competitive nature of the laser market, which is considered a commodity [31][32] - The company is exploring various options for capital allocation, including share buybacks, dividends, and potential M&A opportunities [46][47] Future Growth Potential - Growth in the U.S. market is crucial for margin improvement, as it has historically been the most profitable region for InMode [55][56] - The company is monitoring tariffs closely, as their removal could positively impact margins [56][58] New Product Launches - The Pico laser was launched in Q1 2026, with additional products, including a new version of Morpheus8 and an Erbium laser, expected later in the year [68][72][80] Business Model - InMode maintains a business model that avoids the "razor and razor blade" approach, focusing on device sales without relying heavily on consumables [52][53] Additional Insights - The company is optimistic about the potential for growth in new markets, particularly in women's health, which is projected to be larger than ophthalmology [23] - The focus on bundling products, such as combining RF devices with lasers, is seen as a lucrative strategy to enhance sales [41][42] This summary encapsulates the key insights and strategic directions discussed during the InMode FY Conference, highlighting the company's outlook, organizational changes, product development, and financial strategies.

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 increased by 11% to $242.1 million, compared to $217.2 million in Q4 2024 [15] - Adjusted EBITDA rose to $31.2 million from $26.7 million in Q4 2024, marking a significant increase [20] - For the fiscal year, total revenue reached $961 million, a 7% increase from $895 million in the previous year [21] - Adjusted net income increased by 15% to $102.9 million, or $0.99 per diluted share, compared to $89.7 million, or $0.85 per diluted share in 2024 [21] Business Line Data and Key Metrics Changes - The company operated health and wellness centers on 206 ships at year-end, up from an average of 188 ships in fiscal 2024 [5] - MedSpa services were available on 153 ships, an increase from 147 ships at the end of fiscal 2024 [8] - Revenue per passenger per day and other key operating metrics showed across-the-board increases, reflecting enhanced productivity [8] Market Data and Key Metrics Changes - The company experienced a 2% increase in revenue days and a 1% increase in average guest spend, contributing significantly to revenue growth [16] - The maritime total revenue growth was partially offset by a $1.3 million decrease in destination resorts total revenue due to hotel closures [16] Company Strategy and Development Direction - The company is focusing on innovation and efficiency, including the introduction of AI technologies to enhance operations and revenue generation [10][15] - Strategic decisions included exiting land-based health and wellness centers in Asia and reorganizing operations in the UK and Italy to concentrate on higher growth areas [11][12] - The company plans to introduce health and wellness centers on six new ship builds in 2026, further solidifying its market leadership [6] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving another year of outstanding performance in 2026, supported by strong financial results and strategic initiatives [5][10] - The outlook for 2026 includes expectations for total revenues to exceed $1 billion for the first time, with adjusted EBITDA projected to increase [23] Other Important Information - The company returned nearly $93 million to shareholders through stock buybacks and dividends while reducing outstanding debt [9] - Total cash at year-end was $17.5 million, with total debt net of deferred financing costs at $84 million, down from $98.6 million the previous year [21] Q&A Session Summary Question: Insights on AI integration and its impact on margins - Management confirmed that current guidance does not include potential impacts from AI initiatives, which are expected to show meaningful results in the second half of 2026 [26][27] Question: Consumer trends and pricing strategies - Management noted that while there may be slight additional discounting, overall higher prices are being accepted by consumers, indicating a positive trend in spending [28][29] Question: Dynamic pricing model rollout - The dynamic price optimization model will initially focus on pre-booking across 94% of vessels, with a broader rollout planned for later in the year [32][33] Question: Spa menu reformats - Management confirmed a proactive approach to condensing the spa menu to focus on popular items, aiming to enhance customer choice and increase conversion rates [34][36]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $103.9 million, up from $97.9 million in Q4 2024, while full-year revenue for 2025 totaled $370.5 million, a 6% decrease compared to 2024 [8][9] - Gross margins for Q4 2025 were 78% on a GAAP basis, down from 79% in Q4 2024, while non-GAAP gross margins were 79% for both Q4 and full year 2025 [9][11] - GAAP diluted earnings per share for Q4 2025 were $0.42, compared to $1.14 in Q4 2024, and $1.43 for the full year 2025, down from $2.25 in 2024 [11][12] Business Line Data and Key Metrics Changes - Revenue from consumables and services increased slightly compared to last year, indicating early signs of stabilization in patient activity [4] - Minimally invasive technology platforms accounted for 76% of total revenues in Q4 2025, while consumables and services represented 22% of revenue, up from 20% in 2024 [9][10] Market Data and Key Metrics Changes - Sales outside the U.S. totaled $48.5 million in Q4 2025, representing 47% of total sales and a 38% increase compared to Q4 2024, driven primarily by Europe [9] - For the full year 2025, sales outside the U.S. accounted for $171.8 million, or 46% of total sales, representing a 15% increase compared to 2024 [9] Company Strategy and Development Direction - The company views 2026 as a stabilization year following a prolonged period of industry softness, with plans to continue innovating and introducing new platforms [4][6] - A specialized sales team has been established for the Envision platform, aimed at increasing penetration and improving sales productivity [5] - The company plans to launch two new platforms in 2026, including a Korean-made Pico laser device and a device combining new Morpheus technology with Erbium YAG laser [6] Management's Comments on Operating Environment and Future Outlook - Management noted that the industry has not yet fully recovered from the global economic slowdown, with demand in North America remaining below historical levels, but there are early signs of stabilization [7] - The CEO mentioned that interest rates starting to come down could positively impact leasing packages for capital equipment purchases [17] Other Important Information - The company returned $127.4 million to shareholders through a disciplined share repurchase program [13] - The board of directors is exploring strategic alternatives to improve company value, having engaged Bank of America for assistance [20] Q&A Session Summary Question: What signs suggest improving trends in the market? - Management noted a slight increase in procedures and sales in consumables, along with declining interest rates as positive indicators [17] Question: Can you provide updates on strategic alternatives? - The board is considering several strategic alternatives and has engaged Bank of America for assistance, with management not directly involved in the process [20] Question: What are the expectations for gross margins and EBIT margins? - Management indicated that new product launches, particularly lasers, may impact gross margins, and guidance is conservative based on past experiences [27][28] Question: How is the ApexRF platform performing? - The ApexRF platform is being sold alongside other products without a specialized sales team, and management is awaiting FDA indications before pushing it further [72] Question: What is the contribution of new product launches for 2026? - Two new products are expected to be launched in 2026, with significant marketing efforts planned, although specific financial contributions are not yet provided [41]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $103.9 million, up from $97.9 million in Q4 2024, while full-year revenue totaled $370.5 million, a 6% decrease compared to 2024 [8][9] - Gross margins for Q4 2025 were 78% on a GAAP basis, down from 79% in Q4 2024, while non-GAAP gross margins were 79% for both Q4 and full year 2025 [9][11] - GAAP diluted earnings per share for Q4 were $0.42, compared to $1.14 in Q4 2024, and $1.43 for the full year 2025, down from $2.25 in 2024 [11][12] Business Line Data and Key Metrics Changes - Revenue from consumables and services increased slightly compared to last year, indicating early signs of stabilization in patient activity [4] - Minimally invasive technology platforms accounted for 76% of total revenues in Q4 2025, while consumables and services represented 22% of revenue, up from 20% in 2024 [9][10] Market Data and Key Metrics Changes - Sales outside the U.S. totaled $48.5 million in Q4 2025, representing 47% of total sales and a 38% increase compared to Q4 2024, driven primarily by Europe [9] - For the full year 2025, sales outside the U.S. accounted for $171.8 million, or 46% of total sales, a 15% increase compared to 2024 [9] Company Strategy and Development Direction - The company views 2026 as a stabilization year following a prolonged period of industry softness, with expectations for revenue to be broadly in line with 2025 [4][7] - Product innovation is a key pillar of the strategy, with plans to launch two new platforms in 2026, including a Korean-made Pico laser device and a device combining new Morpheus technology with Erbium YAG laser [6][7] - The sales force is now segmented across aesthetic and wellness, with a dedicated team for specific platforms to drive increased penetration and improve sales productivity [5] Management's Comments on Operating Environment and Future Outlook - Management noted that the industry has not yet fully recovered from the global economic slowdown, with demand in North America remaining below historical levels, but there are early signs of stabilization in the U.S. and gradual improvement in Europe [7] - The CEO mentioned that interest rates starting to come down could positively impact leasing packages for capital equipment purchases, which may encourage more sales [16] Other Important Information - The company returned $127.4 million to shareholders through a disciplined share repurchase program [12] - The board of directors is exploring strategic alternatives to improve company value, having engaged Bank of America for assistance [19] Q&A Session Summary Question: What signs suggest improving trends in the market? - Management noted a slight increase in procedures and sales in consumables, along with declining interest rates as positive indicators [16] Question: Can you provide updates on strategic alternatives? - The board is considering several strategic alternatives to enhance company value, with management not directly involved in the process [19] Question: What are the expectations for gross margins and EBIT margins? - Management indicated that new product launches, particularly lasers, may impact gross margins, and guidance is conservative based on past experiences [27][28] Question: How significant is the laser market for future growth? - The CEO emphasized that laser platforms are essential for growth, despite being in a saturated market with lower margins compared to existing products [31][32] Question: What is the status of the dry eye indication and FDA approval timelines? - The company is working on FDA approval for a bipolar RF device for dry eye treatment, with studies expected to last through 2026 and possibly into 2027 [64][65]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $103.9 million, up from $97.9 million in Q4 2024, while full-year revenue for 2025 totaled $370.5 million, a 6% decrease compared to 2024 [7][8] - Gross margins in Q4 2025 were 78% on a GAAP basis, down from 79% in Q4 2024, while Non-GAAP gross margins remained at 79% for both Q4 and full year 2025 [8][10] - GAAP diluted earnings per share for Q4 were $0.42, compared to $1.14 in Q4 2024, and $1.43 for the full year 2025, down from $2.25 in 2024 [10][11] Business Line Data and Key Metrics Changes - Revenue from consumables and services increased slightly compared to last year, indicating early signs of stabilization in patient activity [4] - Minimally invasive technology platforms accounted for 76% of total revenues in Q4 2025, while consumables and services represented 22% of revenue, up from 20% in 2024 [8] Market Data and Key Metrics Changes - Sales outside the U.S. totaled $48.5 million in Q4 2025, representing 47% of total sales and a 38% increase compared to Q4 2024, driven primarily by Europe [8] - For the full year 2025, international sales accounted for $171.8 million, or 46% of total sales, reflecting a 15% increase compared to 2024 [8] Company Strategy and Development Direction - The company views 2026 as a stabilization year following a prolonged period of industry softness, with a focus on disciplined execution of its product roadmap and maintaining leadership in the aesthetic industry [4][6] - Product innovation remains a key pillar, with plans to launch two new platforms in 2026, including a Korean-made Pico laser device and a device combining new Morpheus technology with Erbium YAG laser [5][6] Management's Comments on Operating Environment and Future Outlook - Management noted that early signs of stabilization in the U.S. market and gradual improvement in Europe could support future performance [6] - The company is encouraged by a slight increase in procedures and sales in consumables, indicating potential recovery in the aesthetic space [16] Other Important Information - The company has returned $127.4 million to shareholders through a disciplined share repurchase program [11] - The board is exploring strategic alternatives to enhance company value, including hiring Bank of America for assistance [19] Q&A Session Summary Question: What signs suggest improving trends in the market? - Management noted declining interest rates and a slight increase in procedures and consumables sales as early signs of improvement [16] Question: Can you provide updates on strategic alternatives? - The board is considering several strategic alternatives to improve company value, with no direct involvement from management in the process [19] Question: What are the expectations for gross margins and EBIT margins? - Management indicated that new product launches, particularly lasers, may impact gross margins, which are expected to be in the neighborhood of 75% [29] Question: How is the ApexRF platform performing? - The ApexRF platform is being sold alongside other products without a specialized sales team, and management is awaiting FDA indications before pushing it further [73] Question: What is the outlook for international revenue? - Management expressed optimism about increasing direct sales in new subsidiaries, but could not definitively state if international revenue would surpass North America [58]

SAFE HARBOR DISCLAIMER • This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this presentation regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predi ...

Company Overview - InMode is a leading global provider of minimally-invasive aesthetic and wellness solutions [5] - The company has 10 patented technologies across 11 product families [7] - InMode sells its products in 88 countries [7] - The company has 656 employees worldwide, including 284 direct sales reps [19] Financial Performance (Q3 2025) - Q3 2025 revenue was $93.2 million [7] - Non-GAAP net income for Q3 2025 was $24.5 million [7] - Non-GAAP gross margin for Q3 2025 was 78% [7] - Non-GAAP diluted earnings per share for Q3 2025 was $0.38 [7] Technology and Market - InMode addresses the "Treatment Gap" with minimally-invasive technologies [26] - RFAL technology can achieve up to 40% soft tissue contraction [40]

Summary of InMode Conference Call Company Overview - **Company**: InMode - **Industry**: Medical Technology, specifically in energy-based, minimally invasive surgical aesthetic and medical treatment solutions Key Points and Arguments Market Conditions - The aesthetic market has been experiencing a slowdown since summer 2023, attributed to macroeconomic factors and softening demand [4][6] - InMode has a strong financial position, being debt-free with a solid cash balance, which allows it to navigate the current market challenges [9] Financing and Credit - Approximately 90% of InMode's capital equipment sales are financed through third-party leasing companies [6] - Rising interest rates have increased monthly payments for customers, leading to tighter credit conditions and more rigorous approval processes [6][7] Product Strategy - InMode has opted not to lower prices, believing it would be detrimental in the long run [16] - The company is expanding its product offerings to include lasers and other technologies, aiming to become a one-stop shop for customers [16][17] Market Penetration - InMode has achieved about 25-30% penetration in the plastic surgeon community but only 5-7% in dermatology, indicating significant growth potential in the latter [20][22] - The company is focusing on upgrading existing customers to newer technologies, which could enhance penetration further [22][32] Patient Demand - There has been a decline in patient demand over the last couple of years, impacting capital equipment sales [58] - Recent months have shown signs of stabilization in demand, although it remains below previous levels [61][63] International Growth - InMode has seen a return to double-digit growth in international markets, attributed to leadership changes and direct operations in countries like Germany and Japan [81][82] - The company is working with a distributor in China and is awaiting approvals for more products, which could enhance sales in that market [87][90] Tariff Impact - The company anticipates a 200-300 basis point headwind from tariffs, with ongoing supply chain adjustments aimed at mitigating this impact [64][70] - Future guidance on tariffs will depend on the success of these adjustments and potential treaties between Israel and the U.S. [69] Future Outlook - InMode is cautiously optimistic about achieving 5-6% revenue growth in the coming years, which would add $25-30 million to the top line annually [94][96] - The company expects new product launches to contribute positively to revenue growth [94] Additional Important Information - The aesthetic space is cyclical, and down cycles typically do not last more than two to three years [12] - The company is actively pursuing opportunities in women's health, which is seen as a significant growth driver [54][56] - InMode is also developing a standalone team focused on ophthalmology, which is expected to boost growth once FDA approvals are secured [53][54]